Background
In the US, untreated latent tuberculosis infection (LTBI) is the primary driver of new tuberculosis (TB) cases. Tracking real-world levels and trends in LTBI testing is therefore critical for assessing TB elimination efforts. However, many studies suggest that LTBI testing among people with high TB risk is suboptimal. To evaluate this practice gap, we conducted a serial cross-sectional study using 15 years of electronic health record data from an integrated health system to assess trends in LTBI testing.
Methods
In this serial cross-sectional study we included all Kaiser Permanente Northern California (KPNC) members aged ≥18 years with at least 6 months of continuous enrollment between January 2008 and December 2023. The primary outcome was LTBI testing with either a tuberculin skin test (TST) or an interferon gamma release assay (IGRA). The secondary outcome was ever receiving an IGRA among persons tested for LTBI. Using multivariable modified Poisson regression, we assessed factors associated with testing, including TB risk factors (born in TB-endemic country, immunosuppressed, close contact with TB, homelessness) specified in US CDC and California-specific screening guidelines.
Results
Among 6,572,839 persons in the study, 1,405,768 (21.4%) were tested for LTBI; 76% of all testing during the study period was among people without any TB risk factors. Of all people tested, 373,659 (26.5%) received an IGRA. The overall LTBI testing rate did not increase substantially during the study period: the rate per 100 population was 5.2 in 2008 and 6.7 in 2023. People born in a TB-endemic country had the lowest rate of LTBI testing with a rate of 3.3 in 2008 and 5.0 in 2023 (Figure). Persons born in a TB-endemic country had a 25.2% (24.8-25.5%) lower prevalence of LTBI testing compared to US-born persons. Persons with TB risk factors including close contact with TB case (PR=2.66 [2.62-2.70]), homelessness (PR=1.29 [1.26-1.32]), and HIV (PR=3.58 [3.53-3.63]) were more likely to receive LTBI testing. Among persons who received any LTBI testing, persons born in TB-endemic countries were 61.7% (60.5-62.9%) more likely to have been tested with an IGRA than US-born persons.
Conclusions
We identified a substantial gap between evidence and practice. Despite data indicating that 82% of all TB cases in California are among persons born in TB-endemic countries, current LTBI testing practices are disproportionately undertesting this population while over testing persons without any TB risk factors.